Evidence map›Paper›PMID 19159454›Full record

ArticleCardiovascular diabetology2009

Effects of streptozotocin-induced diabetes on the pharmacology of rat conduit and resistance intrapulmonary arteries.

Alison M Gurney, Frank C Howarth

Open access · goldAbstract readComparative Study
In one paragraph

Article in Cardiovascular diabetology, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
1.7field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 26 citations in OpenAlex.

  1. Article
  2. Article
  3. Comparison of Pulmonary and Systemic NO- and PGIOxidative medicine and cellular longevity · 2018
    Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 2 institutions in 2 countries.

Alison M GurneyFaculty of Life Sciences, University of Manchester, Floor 2, Core Technology Facility, 46 Grafton Street, Manchester, M13 9NT, UK. alison.gurney@manchester.ac.uk
Frank C Howarth
United Arab Emirates University · AEUniversity of Manchester · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundPoor control of blood glucose in diabetes is known to promote vascular dysfunction and hypertension. Diabetes was recently shown to be linked to an increased prevalence of pulmonary hypertension. The aim of this study was to determine how the pharmacological reactivity of intrapulmonary arteries is altered in a rat model of diabetes.

methodsDiabetes was induced in rats by the beta-cell toxin, streptozotocin (STZ, 60 mg/kg), and isolated conduit and resistance intrapulmonary arteries studied 3-4 months later. Isometric tension responses to the vasoconstrictors phenylephrine, serotonin and PGF2alpha, and the vasodilators carbachol and glyceryl trinitrate, were compared in STZ-treated rats and age-matched controls.

resultsSTZ-induced diabetes significantly blunted the maximum response of conduit, but not resistance pulmonary arteries to phenylephrine and serotonin, without a change in pEC50. Agonist responses were differentially reduced, with serotonin (46% smaller) affected more than phenylephrine (32% smaller) and responses to PGF2alpha unaltered. Vasoconstriction caused by K+-induced depolarisation remained normal in diabetic rats. Endothelium-dependent dilation to carbachol and endothelium-independent dilation to glyceryl trinitrate were also unaffected.

conclusionThe small resistance pulmonary arteries are relatively resistant to STZ-induced diabetes. The impaired constrictor responsiveness of conduit vessels was agonist dependent, suggesting possible loss of receptor expression or function. The observed effects cannot account for pulmonary hypertension in diabetes, rather the impaired reactivity to vasoconstrictors would counteract the development of pulmonary hypertensive disease.

Indexed as

Pulmonary CirculationAnimalsCalcium SignalingCarbacholDiabetes Mellitus, ExperimentalDiabetic AngiopathiesDinoprostEndothelium, VascularHypertension, PulmonaryMaleMembrane PotentialsMuscle, Smooth, VascularNitroglycerinPhenylephrinePotassiumPulmonary ArteryCarbacholDinoprostNitroglycerinPhenylephrinePotassiumSerotoninStreptozocinVasoconstrictor AgentsVasodilator Agents

Identifiers

PMID19159454
PMCPMC2632989
OpenAlexW2085304075

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.